We have recently identified N-epsilon-azelayllysine (AZL) as a carboxyalkylamide-type novel lysine adduct in the reaction of linoleic acid hydroperoxides with the lysine derivative. To examine the formation of AZL in vivo, a novel monoclonal antibody (mAb19D5) specific to AZL moiety was prepared. The mAb19D5 scarcely recognized oxidized low-density lipoprotein (oxLDL), whereas the treatment of oxLDL with alkali or phospholipase A(2) significantly increased the immunoreactivity. Similarly, the immunopositive materials were detected in alkali- or phospholipase A(2)-treated sections from human atherosclerotic aorta but not in untreated sections. These results suggest that esterified lipid hydroperoxide-derived modification of protein may serve as one mechanism for the oxidative modification of LDL and subsequent formation of atherosclerotic lesions in vivo. (C) 2003 Published by Elsevier Inc.
引用
收藏
页码:271 / 276
页数:6
相关论文
共 17 条
[1]
De Montarby L., 1988, TETRAHEDRON LETT, V29, P3895